1. [National guidelines of diagnosis and treatment of the non-Hodgkin lymphoma].
- Author
-
Candelaria M, Cervera-Ceballos E, Meneses-García A, Avilés-Salas A, Lome-Maldonado C, Zárate-Osorno A, Ortiz-Hidalgo C, Rodríguez-Moguel L, Quiñónez-Urrego EE, Ramos-Salazar P, Romero-Guadarrama MB, Lara-Torres C, Ramírez-Aceves R, López-Navarro O, Rivas-Vera S, Díaz-Meneses IE, Estrada-Lobato E, Cervera-Ceballos J, Rojas-Marín CE, Hernández-Rodriguez JM, Pérez-López B, Gómez-Almaguer D, Altamirano-Ley J, Baz P, Valero-Saldaña LM, Navarrete-Herrera JR, Torres-Salgado FG, Solano-Murillo P, Nambo-Lucio Mde J, Rivas-Llamas R, Aquino-Salgado JL, Avila-Arreguín EV, Cortês-Esteban P, Chongo-Alfaro ML, Pérez-Ramírez Ode J, Toledano-Cuevas DV, Lobato-Mendizábal E, Martínez-Ramírez MA, Morales-Maravilla A, Sosa-Camas RE, Agreda-Vásquez GP, Camacho-Hernández A, Aguayo-González A, Espinoza-Zamora JR, Sánchez-Guerrero SA, Lozano-Zavaleta V, Selva-Pallares JE, Hernádez-Rodríguez JM, Cardiel-Silva M, Castillo-Rivera MH, Villela L, Loarca-Piña LM, Zurita-Martínez H, Graham-Casassus J, Azaola-Espinosa P, Silva-López S, Armenta-San Sebastián JA, Mijangos-Huesca F, Pérez-Osorio JE, Aldaco-Sarvide F, Castellanos G, Ramírez-Ibarguen AF, Zapata-Canto N, and Labardini-Méndez JR
- Subjects
- Humans, Mexico, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin therapy
- Abstract
Non-Hodgkin lymphoma comprises a heterogeneous group of haematological malignancies, classified according to their clinic, anatomic-pathological features and, lately, to their molecular biomarkers. Despite the therapeutic advances, nearly half of the patients will die because of this disease. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine. In the face of poor diagnoses devices in most of the Mexican hospitals, we recommend the present diagnose stratification, and treatment guidelines for non-Hodgkin lymphoma, based on evidence. They include the latest and most innovative therapeutic approaches, as well as specific recommendations for hospitals with limited framework and therapy resources.
- Published
- 2013